| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd43e12353298376fd7642260c1dbca |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate |
2015-10-30^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73a68d9aea99bbf6b2b2d1239d241b26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfce3e36e2fdaecc1100f355e9cb481b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd475f1aaced4f847323f729f9b86964 |
| publicationDate |
2016-04-14^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2016053057-A |
| titleOfInvention |
Therapy for diabetic complications |
| abstract |
PROBLEM TO BE SOLVED: To provide a method for enhancing blood glucose control and / or insulin sensitivity in a human subject having diabetic nephropathy and / or metabolic syndrome. A selective ETA receptor antagonist for use in the treatment of a complex state of comorbidity in an elderly diabetic human subject, wherein the selective ETA receptor antagonist is (a) (i) selected (Ii) at least one additional agent that is effective in at least one treatment of the comorbidity other than diabetes and / or hypertension, and optionally (b) selective ETA A selective ETA receptor antagonist that is for administration in combination with or as an adjunct therapy with at least one antihypertensive agent other than a receptor antagonist. [Selection] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017145251-A |
| priorityDate |
2007-08-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |